Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Organisation › Details

FundaMental Pharma GmbH (FMP)

FundaMental Pharma (“FundaMental”) is a neuroscience company, spun out of Heidelberg University, developing first-in-class small molecule inhibitors for treatment of a range of neurodegenerative diseases. FundaMental scientists are developing an entirely new class of drugs that safely counteract glutamate neurotoxicity, a common cause of neurodegeneration. While FundaMental’s current focus is on Amyotrophic Lateral Sclerosis (ALS) and Huntington’s disease, the applicability of these molecules extends to a range of neurogenerative disorders such as Alzheimer’s dementia and aging-related memory loss. *


Period Start 2016-05-12 established (s-off)
  Predecessor University of Heidelberg (Ruperto Carola)
Products Industry molecular spacers (NMDAR/TRPM4 Interface Inhibitors)
  Industry 2 drug development
Persons Person Beher, Dirk (FundaMental Pharma 202404– CEO before Asceneuron + MSD UK + Amgen + Merck Serono)
  Person 2 Schulze, Thomas (FundaMental Pharma 202404– Board Director before CEO before Avontec + november AG + Bayer AG)
Region Region Heidelberg
  Country Germany
  Street 2 Johann-Fischer-Str.
  City 69121 Heidelberg
    Address record changed: 2021-06-23
Basic data Employees n. a.
    * Document for »About Section«: FundaMental Pharma GmbH. (4/11/24). "Press Release: FundaMental Pharma Appoints Dr. Dirk Beher as Chief Executive Officer". Heidelberg.
Record changed: 2024-05-05


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x200px

More documents for FundaMental Pharma GmbH (FMP)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x300px

» top